1. Scrip
  2. >>Business

Enterome Building A Microbiome R&D Presence Via Pharma Deals

 
• By Lubna Ahmed

The number of microbiome-based companies is growing with scientific breakthroughs in this area. Pierre Belichard, CEO of the French gut microbiome focused company Enterome, talked to Scrip at the Biotrinity 2017 meeting in London about its partnerships, pipeline progress and his plans for the future.

French biotech and microbiome-focused Enterome Bioscience SA expects to reveal Phase I data for its lead candidate EB8018, development for Crohn's disease, by the end of July and aims to begin Phase IIa trials soon.

Having secured partnerships with companies including Takeda Pharmaceutical Co. Ltd. and Bristol-Myers Squibb Co., CEO Pierre Belichard tells...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.